Drug for topical application

DATE

January 27, 2021

Background / Context / Abstract:

Conventional oral sirolimus and sirolimus derivatives have been associated with adverse effects due to long-term administration. To solve this problem, the present inventors made a careful examination and as a result, succeeded in developing a cream that efficiently penetrates sirolimus and sirolimus derivatives into the epidermis and accumulates them in the dermis. The drug for topical application of the present invention has been completed.

Technology Overview:

The cream in the present invention can be made by mixing a diethylene glycol ether solution containing sirolimus or sirolimus derivatives with an oil-in-water (O/W) type cream base. The cream is highly effective in treating skin lesions because of the high dermis retaining ability of sirolimus and sirolimus derivatives. In addition, this cream hardly transfers sirolimus or sirolimus derivatives into the blood, and is therefore is excellent in safety.

Benefits:

The cream in the present invention is less likely to cause adverse reactions because it hardly transfers into the blood compared to the conventional oral drugs. In addition, the cream expands the application of sirolimus and sirolimus derivatives such as the optimization of the dosage form by pathology.

Potential Applications / Potential Markets:

We will grant a license from this university to a company and aim at practical application after the conduct of clinical trials by the company.

State of Development / Opportunity / Seeking:

・Available for exclusive and non-exclusive licensing
・Exclusive/non-exclusive evaluation for defined period (set up for options)
・Collaborative/supportive research


※Seeking
1. Development partner
2. Licensing 

IP Status:

WO/2020/184128

Figures:

Efficiency of sirolimus delivery to the dermis and blood for cream (SC), gel (SG), and oral formulation (Oral S) containing sirolimus

Contact:

More Technologies